Text Size

Growth and Development Study of Myozyme (Alglucosidase Alfa).

This study is currently recruiting participants.
Verified March 2013 by Genzyme
Sponsor:
Information provided by (Responsible Party):
Genzyme
ClinicalTrials.gov Identifier:
NCT00486889
First received: June 13, 2007
Last updated: March 14, 2013
Last verified: March 2013
History of Changes
  Purpose

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective of this study is to evaluate the long-term growth and development of patients with infantile-onset Pompe disease with Myozyme (alglucosidase alfa) before 1 year of age. Patients will be followed for 10-year period.


Condition Intervention Phase
Pompe Disease
Glycogen Storage Disease Type II (GSD-II)
Acid Maltase Deficiency Disease
 Biological: alglucosidase alfa
 Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Myozyme (Alglucosidase Alfa).

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Genzyme:

Primary Outcome Measures:
  • Long-term growth and development as measured by recumbent length/height, weight and head circumference [ Time Frame: Every 3 Months for up to 10 years ] [ Designated as safety issue: No ]
  • Change from baseline in motor development and function, as measured by changes in the motor subscale of the Bayley Scales of Infant and Toddler Development (Bayley-III) (up to 42 months of age) at 10 years [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]
  • Change from baseline in motor development and function, as measured by changes in the total score of the Gross Motor Function Measure (GMFM-88) at 10 years [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
  • Change from baseline in the raw scores, normative standard scores and scaled scores for the Functional Skills Mobility and Self-Care domains of the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at 10 years [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
  • Change from baseline in Cognitive Development, as measured by changes in the raw scores, scaled scores and composite scores for the cognitive and language subscales of the Bayley Scales of Infant and Toddler Development (Bayley-III) at 10 years [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
  • Change from baseline in Cognitive Development, as measured by changes in the raw and scaled scores of the modified Leiter International Performance Scale - Revised (Leiter-R) scores (starting at 42 months of age) [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
  • Summary of Adverse Events [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: August 2008
Estimated Study Completion Date: January 2026
Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Myozyme® (alglucosidase alfa) Biological: alglucosidase alfa
Intravenous (IV) infusion: 20mg/kg every 2 weeks
Other Name: Myozyme

  Eligibility

Ages Eligible for Study:   up to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient or patient's legal guardian must provide signed, informed consent prior to performing any study-related procedures;
  • The patient must have a confirmed diagnosis of Pompe disease as determined by deficient endogenous acid alpha-glucosidase (GAA) activity or GAA mutation analysis; and
  • The patient must be <1 year of age at time of study enrollment (and receive Myozyme treatment before 1 year of age), or the patient must be between 1 year and 24 months of age and must have initiated Myozyme treatment prior to turning 1 year of age.

Exclusion Criteria:

  • The patient is participating in another clinical study using Myozyme or any investigational therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00486889

Contacts
Contact: Medical Information 800-745-4447 medinfo@genzyme.com
Contact: Medical Information 617-252-7832 medinfo@genzyme.com

Locations
United States, Florida
Recruiting
Gainesville, Florida, United States
United States, Georgia
Recruiting
Decatur, Georgia, United States
United States, Michigan
Recruiting
Detroit, Michigan, United States
Sponsors and Collaborators
Genzyme
Investigators
Study Director: Medical Monitor Genzyme
  More Information

No publications provided

Responsible Party: Genzyme
ClinicalTrials.gov Identifier: NCT00486889     History of Changes
Other Study ID Numbers: AGLU03606
Study First Received: June 13, 2007
Last Updated: March 14, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Genzyme:
Glycogenesis 2

Additional relevant MeSH terms:
Deficiency Diseases
Glycogen Storage Disease Type II
Glycogen Storage Disease
Malnutrition
Nutrition Disorders
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Carbohydrate Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on May 23, 2013